A Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation
Public ClinicalTrials.gov record NCT07702578. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/3 Study Evaluating the Efficacy and Safety of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a multicenter, genetically-randomized, controlled, Phase 3 study evaluating the efficacy and safety of T-cell receptor-engineered donor T cells targeting HA-2 (TSC-101) administered following reduced-intensity conditioning (RIC) hematopoietic cell transplantation (HCT) in participants with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). The study will compare TSC-101 plus standard of care (SOC) versus SOC alone in participants undergoing allogeneic peripheral blood stem cell transplantation from haploidentical or mismatched unrelated donors.
Study identification
- NCT ID
- NCT07702578
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 310 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 18, 2026 (Actual)
- Primary completion
- Jun 2029 (Estimated)
- Completion
- Jun 2029 (Estimated)
- Last update posted
- Oct 5, 2026
2026 – 2029
United States locations
- U.S. sites
- 26
- U.S. states
- 18
- U.S. cities
- 24
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Banner Health - MD Anderson Cancer Center | Gilbert | Arizona | 85234 | — |
| Honor Health Cancer Transplant Institute | Scottsdale | Arizona | 85258 | — |
| City of Hope | Duarte | California | 91010 | — |
| Stanford - School of Medicine | Stanford | California | 94305 | — |
| University of Colorado - Anschutz Cancer Center | Aurora | Colorado | 80045 | — |
| SCRI - Colorado Blood Cancer Institute | Denver | Colorado | 80218 | — |
| Yale | New Haven | Connecticut | 06510 | — |
| Memorial Cancer Institute | Hollywood | Florida | 33021 | — |
| Moffitt Cancer Institute | Tampa | Florida | 33612 | — |
| Northside Hospital | Atlanta | Georgia | 30342 | — |
| University of Chicago | Chicago | Illinois | 60607 | — |
| The University of Kansas Cancer Center | Kansas City | Kansas | 66160 | — |
| Johns Hopkins University | Baltimore | Maryland | 21287 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| Dana-Farber Cancer Institute - Hematology/Oncology | Boston | Massachusetts | 02215 | — |
| Karmanos Cancer Institute | Detroit | Michigan | 48201 | — |
| Hackensack University Medical Center | Hackensack | New Jersey | 07601 | — |
| Mount Sinai Hospital | New York | New York | 10029 | — |
| Columbia University - Irving Medical Center | New York | New York | 10032 | — |
| The University of North Carolina at Chapel Hill | Chapel Hill | North Carolina | 27599 | — |
| Hospital of the University of Pennsylvania | Philadelphia | Pennsylvania | 19104 | — |
| Sarah Cannon Research Institute - TriStar Bone Marrow Transplant (BMT) | Nashville | Tennessee | 37203 | — |
| St. David's South Austin Medical Center | Austin | Texas | 76704 | — |
| Baylor University Medical Center | Dallas | Texas | 75246 | — |
| The University of Texas - MD Anderson Cancer Center | Houston | Texas | 76704 | — |
| Froedtert & Medical College of Wisconsin | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07702578, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 5, 2026 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT07702578 live on ClinicalTrials.gov.